Tags

Type your tag names separated by a space and hit enter

The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.
Respir Med. 2008 Mar; 102(3):413-21.RM

Abstract

BACKGROUND

The cost of exacerbations in chronic obstructive pulmonary disease (COPD) has not been well studied. The aim of this study was to identify and quantify the (average) cost of moderate and severe exacerbations (ME and SE, respectively) from a Canadian perspective.

METHODS

Resources used during ME and SE were identified in a year long prospective, observational study (Resource Utilization Study In COPD (RUSIC)). The units of analysis were ME and SE. Unit costs (2006$CAN), based on provincial, hospital and published sources, were applied to resources. The overall cost per ME and SE were calculated. The population burden of exacerbations was also calculated.

RESULTS

Among study participants (N=609, aged 68.6+/-9.4 years, 58.3% male) there were 790 exacerbations: 639 (80.9%) MEs and 151 (19.1%) SEs. Of the 790 exacerbations, 618 (78.2%), 245 (31.0%) and 151 (19.1%) included a visit to an outpatient clinic, emergency department (ED) or hospital, respectively. For ME, 85.9% and 13.1% involved visits to GPs and respirologists, respectively. Pharmacologic treatment changes in the outpatient setting involved antibiotics (63.1%) and corticosteroids (34.7%). The overall mean costs for outpatient and ED services for MEs were $126 (N=574) and $515 (N=105), respectively. The average overall cost of a ME was $641. For SEs, the average hospital stay was 10.0 days. The overall mean costs of outpatient, ED and hospitalization services for SE were $114 (N=44), $774 (N=140) and $8669 (N=151), respectively. The average overall cost of a SE was $9557.

CONCLUSION

The economic burden associated with MEs and especially SEs, in Canada, is considerable and likely has a substantial impact on healthcare costs. The overall burden of exacerbations has been estimated in the range of $646 million to $736 million per annum.

Authors+Show Affiliations

Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Division of Clinical Pharmacology, Sunnybrook Research Institute, Department of Pharmacology, University of Toronto, Ontario, Canada. nicole.mittmann@sunnybrook.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18086519

Citation

Mittmann, N, et al. "The Cost of Moderate and Severe COPD Exacerbations to the Canadian Healthcare System." Respiratory Medicine, vol. 102, no. 3, 2008, pp. 413-21.
Mittmann N, Kuramoto L, Seung SJ, et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med. 2008;102(3):413-21.
Mittmann, N., Kuramoto, L., Seung, S. J., Haddon, J. M., Bradley-Kennedy, C., & Fitzgerald, J. M. (2008). The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respiratory Medicine, 102(3), 413-21.
Mittmann N, et al. The Cost of Moderate and Severe COPD Exacerbations to the Canadian Healthcare System. Respir Med. 2008;102(3):413-21. PubMed PMID: 18086519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. AU - Mittmann,N, AU - Kuramoto,L, AU - Seung,S J, AU - Haddon,J M, AU - Bradley-Kennedy,C, AU - Fitzgerald,J M, Y1 - 2007/12/20/ PY - 2007/05/14/received PY - 2007/10/09/revised PY - 2007/10/12/accepted PY - 2007/12/19/pubmed PY - 2008/8/12/medline PY - 2007/12/19/entrez SP - 413 EP - 21 JF - Respiratory medicine JO - Respir Med VL - 102 IS - 3 N2 - BACKGROUND: The cost of exacerbations in chronic obstructive pulmonary disease (COPD) has not been well studied. The aim of this study was to identify and quantify the (average) cost of moderate and severe exacerbations (ME and SE, respectively) from a Canadian perspective. METHODS: Resources used during ME and SE were identified in a year long prospective, observational study (Resource Utilization Study In COPD (RUSIC)). The units of analysis were ME and SE. Unit costs (2006$CAN), based on provincial, hospital and published sources, were applied to resources. The overall cost per ME and SE were calculated. The population burden of exacerbations was also calculated. RESULTS: Among study participants (N=609, aged 68.6+/-9.4 years, 58.3% male) there were 790 exacerbations: 639 (80.9%) MEs and 151 (19.1%) SEs. Of the 790 exacerbations, 618 (78.2%), 245 (31.0%) and 151 (19.1%) included a visit to an outpatient clinic, emergency department (ED) or hospital, respectively. For ME, 85.9% and 13.1% involved visits to GPs and respirologists, respectively. Pharmacologic treatment changes in the outpatient setting involved antibiotics (63.1%) and corticosteroids (34.7%). The overall mean costs for outpatient and ED services for MEs were $126 (N=574) and $515 (N=105), respectively. The average overall cost of a ME was $641. For SEs, the average hospital stay was 10.0 days. The overall mean costs of outpatient, ED and hospitalization services for SE were $114 (N=44), $774 (N=140) and $8669 (N=151), respectively. The average overall cost of a SE was $9557. CONCLUSION: The economic burden associated with MEs and especially SEs, in Canada, is considerable and likely has a substantial impact on healthcare costs. The overall burden of exacerbations has been estimated in the range of $646 million to $736 million per annum. SN - 0954-6111 UR - https://www.unboundmedicine.com/medline/citation/18086519/The_cost_of_moderate_and_severe_COPD_exacerbations_to_the_Canadian_healthcare_system_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(07)00432-5 DB - PRIME DP - Unbound Medicine ER -